Abstracts tagged "autoimmune diseases"

Abstract Number: 0862 • ACR Convergence 2025
In immune-mediated necrotising myopathy, anti-HMGCR antibodies inhibit HMGCR activity, leading to the sarcoplasmic accumulation of lipid droplets and myofibres necrosis
Margherita Giannini¹, Giulia Quiring², Mustapha Oulad-Abdelghani³, Béatrice Lannes¹, Yves Allenbach⁴, Olivier Benveniste⁵, Olivier Boyer⁶, Aleksandra Nadaj Pakleza¹, Bernard Geny⁷ and Alain Meyer⁸, ¹Strasbourg University Hospital, Strasbourg, France, ²University of Strasbourg, Strasbourg, France, ³IGBMC, Strasbourg, France, ⁴SORBONNE UNIVERSITE, Paris, France, ⁵Sorbonne Uniersite, Hopital de la Pitie-Salpetriere, Paris, France, ⁶University of Rouen, Rouen, France, ⁷UR ³⁰⁷², Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; FranceExplorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg;, Strasbourg, Alsace, France, ⁸Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Explorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, UR ³⁰⁷², Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; France, Strasbourg, Alsace, France
Background/Purpose: The aim of this study was to investigate whether in immune-mediated necrotising myopathy (IMNM), anti-HMGCR antibodies interfere with HMGCR activity and have a myopathic…
Abstract Number: 0471 • ACR Convergence 2025
An Open-label, Randomized, Controlled Phase 1/2 Study to Assess the Safety and Efficacy of KYV-101 Anti-CD19 CAR-T Cell Therapy in Active and Difficult-to-treat ACPA positive Rheumatoid Arthritis: Preliminary Results of the COMPARE Trial
Fredrik Albach¹, Ioanna Minopoulou¹, Artur Wilhelm², Robert Biesen¹, Arnd Kleyer¹, Norman Drzeniek³, Edgar Wiebe⁴, Anja Fleischmann³, Dominic Borie⁵, Vincent Casteleyn³, Tobias Alexander³, Christian Furth⁶, Jan Zernicke³, Burkhard Muche⁷, Sandra Hermann⁴, Pfeil Alexander⁸, Veronika Scholz³, Elpida Phithak³, Olaf Penack⁹, Kamran Movassaghi⁹, Eva Vanessa Schrezenmeier¹⁰, Udo Schneider³, Antonia Busse¹¹, Georg Schett¹², Ulrich Keller¹¹, Lars Bullinger⁹, Gerhard Krönke¹³, Marie Luise Hütter-Krönke¹⁴ and David Simon¹⁵, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁵Kyverna Therapeutics, Emeryville, CA, ⁶Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany, Berlin, ⁷Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁸Department of Internal Medicine III, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany, ⁹Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany, Berlin, ¹⁰Department of Nephrology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, ¹¹Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Campus Steglitz, Berlin, Germany; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany; German Cancer Consortium (DKTK) partner site Charité Berlin and German Cancer Research Center (DKFZ), Heidelberg, Germany, Berlin, ¹²Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ¹⁴Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Campus Steglitz, Berlin, Germany, Berlin, ¹⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by autoreactive B cells that produce anti-citrullinated protein antibodies (ACPA), contributing to sustained synovial inflammation…
Abstract Number: 0277 • ACR Convergence 2025
A Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Ascending Doses and Food Effects of BGB-45035, a chimeric degradation activating compound (CDAC), in Healthy Participants
Vaibhav Mundra¹, Cunjing Yu², Roland Morley¹, Yuan Yuan³, Yifan Qin³, Jingjing Schneider¹, Shengnan Chen³, Zhenyuan Zhou³ and Zhen Yao², ¹BeOne Medicines USA, Inc., San Carlos, CA, ²BeOne Medicines (Beijing) Co, Ltd., Beijing, China (People's Republic), ³BeOne Medicines (Shanghai) Co, Ltd., Shanghai, China (People's Republic)
Background/Purpose: Interleukin 1 receptor associated kinase 4 (IRAK4) degradation may modulate toll-like receptor signaling and alleviate symptoms in rheumatoid arthritis and atopic dermatitis.1,2 BGB-45035, an…
Abstract Number: 0236 • ACR Convergence 2025
Safety and Efficacy of T Cell Engager Therapy in patients with refractory Autoimmune Disease
Laura Bucci¹, Sebastian Böltz¹, Melanie Hagen¹, Danae-Mona Nöthling¹, Tobias Rothe², Carlo Tur¹, Andreas Wirsching¹, Janina Auth³, jochen wacker¹, Markus Eckstein⁴, Stefano Alivernini⁵, Aline Bozec¹, Christina Bergmann¹, Maria Antonietta D'Agostino⁶, Maria Gabriella Raimondo¹, Georg Schett⁷ and Ricardo Grieshaber-Bouyer⁸, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlagen, Germany, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁵Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁶Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸University Hospital Erlangen, Erlangen, Germany
Background/Purpose: T cell engagers (TCEs) are a promising therapeutic strategy to treat autoimmune diseases (AID). However, long-term data remain limited.Methods: Patients with treatment-refractory AID were…
Abstract Number: 0124 • ACR Convergence 2025
Single-cell atlas reveals the central-and-peripheral immune remodeling mechanism and clinical benefits of talitacicept therapy in patients with primary antiphospholipid syndrome
Haoyu Pan¹, Shiyan Gu¹, Xiaohan Wei², Yuying Fan¹, Jinyi Qian¹, Shuyi Yu¹ and Hui Shi³, ¹Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ²Shanghai JiaoTong University, Shanghai, China (People's Republic), ³Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: To elucidate the molecular and cellular mechanisms underlying Talitacicept therapy in primary antiphospholipid syndrome (PAPS) patients using integrated single-cell RNA and TCR/BCR profiling of…
Abstract Number: 0018 • ACR Convergence 2025
Development of a noval ‘1+1+1’ CD19- and BCMA-dual targeted T cell engager for autoimmune diseases
Lin Huan, Hao Ran, Shiyi Wang, Xiaoping Zhang, Bing Yang, Yang He, Dandan Liu, Chenpeng Su, Chuan Chen, Xiaoqian Chen, Kezhen Ye, Liang Tian, Jian Peng and Zhenping Zhu, Helixon Therapeutics, New York
Background/Purpose: B cells and autoantibodies play a central role in the pathogenesis of various autoimmune diseases. Although CD19-targeted B cell depletion shows promising therapeutic potential,…
Abstract Number: 2605 • ACR Convergence 2025
Do Patients Recall Their Rheumatic Diagnoses Accurately? A Comparison by Disease Type
Sydney Liles¹, Samantha Namit², Jennifer Copson³, Matthew Librizzi², Sophia Baionno², Nurten Gizem Tore², Yvonne Lee⁴ and Daniel K. White¹, ¹University of Delaware, Newark, DE, ²University of Delaware, Newark, ³University of Delaware, Wilmington, DE, ⁴Northwestern University, Chicago, IL
Background/Purpose: Rheumatic diseases represent a major public health concern in the United States due to their high prevalence and their association with disability. Observational studies…
Abstract Number: 2525 • ACR Convergence 2025
Point-of-Care Risk Factors for Systemic Disease in Patients Presenting with Small Vessel Vasculitis of the Skin
Arjun Mahajan¹, William Song², Andrew Walls³, Arash Mostaghimi³, Robert Micheletti² and Evan Piette³, ¹Harvard Medical School, Boston, ²Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ³Brigham and Women's Hospital, Harvard Medical School, Boston
Background/Purpose: Small vessel vasculitis (SVV) presenting in the skin may be skin-limited or a manifestation of systemic vasculitis or an underlying autoimmune disease. However, no…
Abstract Number: 2398 • ACR Convergence 2025
Analytical performance of the HEp-2 substrate Diagnostic Kit for ANA as an initial step in the evaluation of a novel Fully Automated IFA Analyzer in a laboratory in England
Jason Sillitoe¹, Ewa Fiorentino-Rozek², Gerber Gomez³, Christian Fischer³ and Caroline Wilson¹, ¹North East Innovation Lab, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ²Clinical Affairs, AliveDx Suisse SA, Eysins, Vaud, Switzerland, ³Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland
Background/Purpose: Indirect immunofluorescence assay (IFA) on HEp-2 cells (HEp-2 IFA) remains a key tool in the diagnostic work-up of autoimmune connective tissue diseases (CTD). Traditionally…
Abstract Number: 2030 • ACR Convergence 2025
Krebs von den Lungen 6 levels (∆KL6) is a reliable marker of disease activity and response to therapy in CTD-ILD
fredeswinda Romero-Bueno¹, lydia Abasolo Alcazar², Mª Jesus Rodriguez-Nieto³, Cristina Vadillo Font⁴, Maria asuncion Nieto⁴, Laura Cebrian⁵, Belen Lopez Muñiz⁶, Jesus Loarce Martos⁷, Juan A Rigual⁷, Hilda Godoy Tundidor⁸, Rosalia Laporta⁹, Irene Llorente Cubas¹⁰, Gema Bonilla¹¹, Luis Gomez Carrera¹², Rosario Garcia Vicuña¹³, Ana Jaureguizar⁷, Jose Luis Morell Hita⁷, Claudia Valenzuela¹⁰ and Olga Sanchez Pernaute¹⁴, ¹University Hospital Fundación Jiménez Díaz"", Madrid, Spain, ²IdISSC. HCSC, Madrid, Madrid, Spain, ³Fundacion Jimenez Diaz (IIS-HUFJD), Madrid, Spain, ⁴Hospital Clínico S Carlos, Madrid, Spain, ⁵Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain, ⁶Hospital Universitario Infanta Leonor, Madrid, Spain, ⁷Hospital Ramón y Cajal, Madrid, Spain, ⁸Hospital Universitario puerta de hierro, Madrid, Spain, ⁹Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁰Hospital Universitario Princesa, Madrid, Spain, ¹¹Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Hospital Universitario de la Princesa, Madrid, Spain, ¹⁴Clinica Universidad de Navarra, Madrid, Madrid, Spain
Background/Purpose: Krebs von den Lungen-6 (KL6) is produced by type 2 alveolar epithelial cells. High circulating KL6 levels show a good accuracy in the diagnosis…
Abstract Number: 1861 • ACR Convergence 2025
Accelerated and Gene-Specific Patterns of Clonal Hematopoiesis Distinguish Subtypes of Systemic Sclerosis
Brecca Miller¹, Shervin Assassi², Maureen Mayes³, alejandro Molina⁴, Kelly Ruggles⁵, David Beck⁶ and Meng Zhang⁷, ¹Center for Human Genetics and Genomics, NYU Grossman School of Medicine, Brooklyn, NY, ²Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ³UT Health Houston Division of Rheumatology, Houston, TX, ⁴Georgia Institute of Technology, Atlanta, GA, ⁵NYU Grossman School of Medicine, Brooklyn, NY, ⁶Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY, ⁷UTHealth Houston Division of Rheumatology, Houston
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by widespread fibrosis, vasculopathy, autoantibody presence, and high mortality in its diffuse subtype with limited effective…
Abstract Number: 1697 • ACR Convergence 2025
Dynamic Effects of T cell Engager Therapy on B and T cells in Autoimmune Disease.
Laura Bucci¹, Tobias Rothe², Ann-Kathrin Goetz³, Kirill Anoshkin¹, Danae-Mona Nöthling¹, Melanie Hagen¹, Sebastian Böltz¹, Andreas Wirsching¹, Georg Schett⁴ and Ricardo Grieshaber-Bouyer⁵, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlagen, Germany, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, ⁴Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁵University Hospital Erlangen, Erlangen, Germany
Background/Purpose: Treatment of autoimmune disease with T cell engagers (TCEs) leads to profound peripheral B cell depletion, followed by their reconstitution. However, the dynamics of…
Abstract Number: 1544 • ACR Convergence 2025
Voclosporin in Lupus Nephritis: Meta-Analysis of 6-Month and 1-Year Efficacy with 1-Year Safety Outcomes
Sri Laxmi Priya Sunkara¹, Ravi Medarametla², Megha Kotha³ and Wael Jarjour⁴, ¹White river medical center, batesville, AR, ²Mamata Medical College, Guntur, Andhra Pradesh, India, ³Ohio State University, Columbus, OH, ⁴The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN), is the most sever organ manifestation of systemic lupus erythematosus (SLE) and it contributes significantly to morbidity and mortality. . Standard…
Abstract Number: 1394 • ACR Convergence 2025
Burden of Comorbidities Across EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains: Treatment Prevalence Among Commercially Insured Sjögren’s Patients in the United States
Minoti Ganguli, Annie Kilby, Ahva Shahabi and Tsu-Chieh Jay Lin, Amgen Inc., Thousand Oaks, CA
Background/Purpose: Sjögren’s disease (SjD) is a systemic disorder characterized by exocrine gland inflammation, leading to dry eyes/mouth, and multiple organ systems involvement1. The European League…
Abstract Number: 1210 • ACR Convergence 2025
Artificial Intelligence-Based Capillaroscopy and Laboratory Biomarkers to Predict Disease Activity in Idiopathic Inflammatory Myopathies: Preliminary Data from the CapIAMI Cohort
Gema María Lledó Ibáñez¹, Jorge Álvarez-Troncoso², Borja del Carmelo Gracia Tello³, Sergio Prieto-Gonzalez⁴, Elena Martínez Robles⁵, Diana Cristina-Varela⁶, Sebastián Molina-Ríos⁷, Luis Sáez Comet⁸, Eiman Soliman⁹, Franklin Uguña¹⁰, Miguel Antonio Mesa¹¹, Miguel Martín Cascón¹², Tânia Santiago¹³, Grace-Jimena Santamaría-Peñaloza¹⁴, Tsvetoslav Georgiev¹⁵, Santiago Bernal-Macias¹⁶, Begoña Marí-Alfonso¹⁷, Jesus Ballano Rodríguez-Solís¹⁸, Sally Patricia Pino Hernández¹⁹, Jacek Olas²⁰, Juan Manuel Mosquera Angarita²¹, Elena García- Guijarro²², Isabel Perales Fraile²³, Mayka Freire Dapena²⁴, Iván Pérez de Pedro²⁵, Luis Adrián Viteri Noël²⁶ and Eduardo Ramos ibáñez²⁷, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Hospital Universitario La Paz, Madrid, Madrid, Spain, ³Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ⁴Hospital Clinic, Barcelona, Catalonia, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Unidad de Reumatología, Hospital General de Medellín, Medellín, Colombia, Medellín, Colombia, ⁷Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, ⁸Hospital Universitario Miguel Servet, Zaragoza, Spain, ⁹Alexandria Faculty of Medicine, Alexandria, Egypt, ¹⁰Sociedad Ecuatoriana de Reumatologia, Quito, Ecuador, ¹¹Universidad Pontificia Bolivariana, Medellin, Colombia, ¹²Hospital General Universitario Morales Meseguer, Murcia, Spain, ¹³ULS de Coimbra, Coimbra, Portugal, ¹⁴Hospital Metropolitano, Quito, Ecuador, ¹⁵Hospital St. Marina, Varna, Varna, Bulgaria, ¹⁶Hospital Universitario San Ignacio, Bogotá, Colombia, ¹⁷Hospital Universitario Parc Taulí, Barcelona, Spain, ¹⁸Hospital Universitario del Henares, Alcalá de Henares, Madrid, Spain, ¹⁹Asoreuma, Care for Kids, Bogota, Distrito Capital de Bogota, Colombia, ²⁰MCRIiR, Szpital Specjalistyczny im. J. Dietla w Krakowie, Cracow, Poland, ²¹Hospital Sant Joan de Déu, Barcelona, Spain, ²²Hospital Universitario Infanta Cristina, Madrid, Spain, ²³Hospital Universitario Infanta Sofía, Madrid, Spain, ²⁴Hospital Clínico Universitario de Santiago de Compostela, La Coruña, Spain, ²⁵Hospital Regional Universitario de Málaga, Málaga, Spain, ²⁶Hospital Universitario Ramón y Cajal, Madrid, Spain, ²⁷Capillary.io, Zaragoza, Aragon, Spain
Background/Purpose: Nailfold videocapillaroscopy (NVC) is a valuable non-invasive tool for assessing microvascular damage in autoimmune diseases. However, its application in idiopathic inflammatory myopathies (IIM) remains…

« Previous Page
1
…
4
5
6
7
8
…
101
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].